{ }
RxSight, Inc. has been upgraded to a Buy rating by UBS, highlighting its innovative approach in the medical device sector. The company specializes in enhancing post-cataract surgery vision through its RxSight Light Adjustable Lens System, which allows for customized visual acuity adjustments using a photosensitive intraocular lens and a light delivery device. This technology aims to surpass traditional IOL options, providing surgeons with a reliable solution for improved patient outcomes.
RxSight, Inc. is a medical technology company focused on enhancing vision post-cataract surgery through its innovative RxSight Light Adjustable Lens System. This system includes the RxSight Light Adjustable Lens, which adapts to UV light patterns, allowing for personalized visual correction after standard cataract procedures. By addressing limitations of traditional intraocular lenses, RxSight aims to significantly improve patient visual outcomes.
RxSight, Inc., a medical device company specializing in light adjustable intraocular lenses for cataract surgery, has 78.78% of its stock owned by institutional investors. Analysts have given the stock a "Buy" rating, with price targets ranging from $52 to $72, indicating potential upside. Recent insider sales have occurred, with insiders owning 9.36% of the company.
UBS has initiated coverage on RxSight Inc. (NASDAQ: RXST) with a Buy rating and a price target of $52, citing strong growth potential in the U.S. cataract surgery market, particularly for its Light Adjustable Lens (LAL) technology. The company is projected to achieve over 20% sales growth through 2028, with a current ratio of 12.67 and minimal debt, positioning it for continued expansion. In Q3 2024, RxSight reported a 59% revenue increase to $35.3 million, driven by LAL sales, and plans to deepen market penetration in North America while expanding globally in 2025.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.